Arbutus Biopharma Corporation

LSE:0SGC Stock Report

Market Cap: US$651.9m

Arbutus Biopharma Management

Management criteria checks 3/4

Arbutus Biopharma's CEO is Mike McElhaugh, appointed in Nov 2022, has a tenure of 2.25 years. total yearly compensation is $1.62M, comprised of 29.8% salary and 70.2% bonuses, including company stock and options. directly owns 0.72% of the company’s shares, worth $4.71M. The average tenure of the management team and the board of directors is 2.8 years and 6.3 years respectively.

Key information

Mike McElhaugh

Chief executive officer

US$1.6m

Total compensation

CEO salary percentage29.8%
CEO tenure2.3yrs
CEO ownership0.7%
Management average tenure2.8yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mike McElhaugh's remuneration changed compared to Arbutus Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$77m

Jun 30 2024n/an/a

-US$77m

Mar 31 2024n/an/a

-US$74m

Dec 31 2023US$2mUS$483k

-US$73m

Sep 30 2023n/an/a

-US$75m

Jun 30 2023n/an/a

-US$73m

Mar 31 2023n/an/a

-US$70m

Dec 31 2022US$1mUS$449k

-US$69m

Sep 30 2022n/an/a

-US$69m

Jun 30 2022n/an/a

-US$76m

Mar 31 2022n/an/a

-US$85m

Dec 31 2021n/an/a

-US$88m

Sep 30 2021n/an/a

-US$87m

Jun 30 2021n/an/a

-US$84m

Mar 31 2021n/an/a

-US$79m

Dec 31 2020US$1mUS$415k

-US$76m

Compensation vs Market: Mike's total compensation ($USD1.62M) is about average for companies of similar size in the UK market ($USD1.47M).

Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.

CEO

Mike McElhaugh (50 yo)

2.3yrs

Tenure

US$1,620,485

Compensation

Mr. Michael J. McElhaugh, also known as Mike, co-founded Arbutus Biopharma Inc. in 2012 and serves as its Interim President and Chief Executive Officer and Director since January 1, 2024. Mr. McElhaugh had...

Leadership Team

NamePositionTenureCompensationOwnership
Michael McElhaugh
Co-Founder2.3yrsUS$1.62m0.72%
$ 4.7m
David Hastings
CFO & Chief Accounting Officer6.7yrsUS$1.46m0.031%
$ 200.8k
Lisa Caperelli
Vice President of Investor Relations3.4yrsno datano data
J. Naftzger
General Counsel1.6yrsno data0.012%
$ 78.6k
Shannon Briscoe
Vice President of Human Resourcesno datano datano data
Karen Sims
Chief Medical Officer1.6yrsno data0.015%
$ 100.5k
R. Mackay-Dunn
Corporate Secretary14.8yrsno datano data

2.8yrs

Average Tenure

57yo

Average Age

Experienced Management: 0SGC's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Michael McElhaugh
Co-Founder1.1yrsUS$1.62m0.72%
$ 4.7m
Richard Henriques
Independent Non-Executive Director10.2yrsUS$174.24k0.00053%
$ 3.5k
Daniel Burgess
Independent Director7.9yrsUS$161.74k0%
$ 0
Keith Manchester
Independent Non-Executive Director9.9yrsUS$156.74k0.024%
$ 158.5k
Adrian Di Bisceglie
Member of Scientific Advisory Boardno datano datano data
Charles Rice
Member of Scientific Advisory Boardno datano datano data
James Meyers
Independent Director6.3yrsUS$176.74k0%
$ 0
William Symonds
Chairman of Scientific Advisory Board6.3yrsno datano data
Frank Torti
Independent Chairman of the Board of Directors6.3yrsUS$187.99k0%
$ 0
Fabien Zoulim
Member of Scientific Advisory Boardno datano datano data
Scott Biller
Member of Scientific Advisory Boardno datano datano data
Ulrike Protzer
Member of Scientific Advisory Boardno datano datano data

6.3yrs

Average Tenure

57.5yo

Average Age

Experienced Board: 0SGC's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/21 11:28
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Arbutus Biopharma Corporation is covered by 27 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Brian SkorneyBaird
David MartinBloom Burton & Co.